AKT1 and prostate carcinoma: Abnormal activation of the PTEN/AKT/mTOR pathway is the most frequent event in prostate cancer [47] and it is, therefore, important to identify the cofactors modulating prostate cancer progression in the context of altered PTEN/AKT/mTOR signaling.